Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria

Table 2

Overview of adverse events.

Adverse events	All grades (%)	Grade 1 (%)	Grade 2 (%)	Grade 3 (%)	Grade 4 (%)
Hypertension	71	19	26	26	0
Decreased weight	70	30	33	7	0
Fatigue	59	33	26	0	0
Proteinuria	48	29	19	0	0
Diarrhea	44	26	9	7	2
Decreased appetite	23	14	9	0	0
Asthenia	21	19	2	0	0
Palmar-plantar erythrodysesthesia syndrome	14	12	0	2	0
Electrolyte derailment	14	12	2	0	0
Vomiting	7	7	0	0	0
QT-prolongation	5	5	0	0	0
Mouth dryness	5	5	0	0	0
Liver dysfunction	2	0	2	0	0